PMV Pharmaceuticals (PMVP) to Release Earnings on Thursday

Key Points

• PMV Pharmaceuticals is set to release its Q2 2025 earnings on August 14th, with analysts expecting a loss of ($0.39) per share.
• The stock has seen a 2.7% increase recently, opening at $1.52, and has a market cap of approximately $78.96 million.
• Insider activity has been notable, with CEO David Henry Mack selling 58,411 shares, reducing his ownership by 9.82%.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PMV Pharmaceuticals Price Performance

Shares of PMVP traded up $0.03 during trading hours on Friday, hitting $1.48. The stock had a trading volume of 198,562 shares, compared to its average volume of 288,180. The company's fifty day moving average is $1.22 and its two-hundred day moving average is $1.17. PMV Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $1.82. The stock has a market capitalization of $76.89 million, a price-to-earnings ratio of -0.94 and a beta of 1.52.

Insider Activity

In other PMV Pharmaceuticals news, CEO David Henry Mack sold 58,411 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $61,915.66. Following the sale, the chief executive officer owned 536,133 shares of the company's stock, valued at $568,300.98. This represents a 9.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deepika Jalota sold 33,065 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total transaction of $35,048.90. Following the sale, the insider directly owned 89,959 shares in the company, valued at approximately $95,356.54. This represents a 26.88% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,627 shares of company stock worth $121,505. 7.57% of the stock is owned by insiders.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.